Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: GenomeWeb s Weekly Personnel Roundup of the Genomics Sector: Feb 27, 2002

NEW YORK, Feb. 27 - German proteomics company Protagen on Wednesday said it has appointed Christoph H ls to be CEO and head of the company's management board.


Protagen also said that Helmut Meyer will become chief scientific officer, and Martin Bl ggel will be chief operating officer and head of bioinformatics. Both men are company founders.


Lastly, Alex Kleeman has be chosen to be the new head of Protagen's board of directors, the company said. Achim Riemann was tapped to replace him.



Privately held proteomics firm BSI Proteomics has promoted Mark Sawicki to the post of director of structural biology, the company said on Feb. 25.


Sawicki has been a senior structural biologist at the Gaithersburg, Md.-based firm since he joined it 2000, BSI said.


In his new position, Sawicki will "oversee all scientific aspects ... including setting the research agenda, acting as chief scientific liaison to companies that BSI partners with, and directing all research programs," according to the firm.


Before joining BSI, Sawicki was a faculty research director at the Center for Advanced Research in Biotechnology at the University of Maryland.



Pharsight has tapped Michael Perry to replace Art Reidel as president and chief executive officer, the company said on Feb. 25. Reidel will remain with Pharsight as chairman of the board.


Perry comes to Pharsight from Baxter Global Biopharmaceuticals, where he was the worldwide head of research and development for two years. He also was president and CEO of SyStemix, between 1997 and 2000, and Genetic Therapy, from 1998 to 2000. Both companies are subsidiaries of Sandoz/Novartis.


"Mike Perry brings to Pharsight a unique combination of extensive operational background and deep experience in, and vision for, how pharmaceutical research and development can be improved," Reidel said in a statement.



AxCell Biosciences, a unit of Cytogen, has appointed Axel Ullrich to its scientific advisory board, the company said on Feb. 21. 


Ullrich, who specializes in cellular communication and cancer, has been the director and head of the Max-Planck institute for biochemistry since 1988. He also was a co-founder of Sugen, in 1991, and Axxima, in 1998.



Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] PEOPLE, a roundup of personnel comings and goings in genomics, appears each Wednesday.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.